Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.

Fiche publication

Date publication

septembre 2018


Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique


Membres identifiés du Cancéropôle Est :

Tous les auteurs :
Berriolo-Riedinger A, Becker S, Casasnovas O, Vander Borght T, Édeline V


Fluorodeoxyglucose (FDG) positons emission tomography (PET)-computed tomography (CT) is used in many ways at baseline and during the treatment of patients with Hodgkin lymphoma. Many properties of the technique are used in the different steps of patient's management. Initial staging with PET-CT is more accurate than conventional imaging and PET-CT also became the gold standard imaging at the end of treatment with a negative PET-CT mandatory for reaching a complete remission. Early assessment of response by PET-CT is one of the most powerful prognostic factors for progression-free survival of patients with localized and advanced stages and allows guiding treatment. Conversely, previous studies showed that there is no role of FDG PET-CT for the patient's follow-up.

Mots clés

Antineoplastic Agents, therapeutic use, Clinical Decision-Making, Fluorodeoxyglucose F18, Hematopoietic Stem Cell Transplantation, Hodgkin Disease, diagnostic imaging, Humans, Lymph Nodes, diagnostic imaging, Lymphatic Irradiation, Neoplasm Staging, methods, Neoplasm, Residual, diagnostic imaging, Positron Emission Tomography Computed Tomography, Prognosis, Radiopharmaceuticals, Radiotherapy, Image-Guided


Cancer Radiother. 2018 Sep;22(5):393-400